It has been demonstrated that the growth of MTAP-lacked tumor cells is abrogated by PRMT5 inhibition, making PRMT5 a synthetic lethal target for MTAP-lacked tumors (Mavrakis et al., 2016). The gene discussed is PRMT5; the disease is neoplasm.